Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Jan;38(1):134–137. doi: 10.1128/aac.38.1.134

In vitro susceptibilities of rapidly growing mycobacteria to newer antimicrobial agents.

N Khardori 1, H Nguyen 1, B Rosenbaum 1, K Rolston 1, G P Bodey 1
PMCID: PMC284409  PMID: 8141567

Abstract

The in vitro antimicrobial susceptibilities of 42 isolates of rapidly growing mycobacteria (Mycobacterium fortuitum, M. chelonae, and Mycobacterium species [other than M. fortuitum and M. chelonae]) to nine quinolones, including newer agents, two new aminoglycosides, and an aminocyclitol (trospectomycin) were determined by a broth microdilution method. The new quinolones, PD 117596, PD 127391, and PD 117558, showed excellent in vitro activities against M. fortuitum (MICs for 90% of isolates [MIC90s], 0.06, 0.06, and 0.12 microgram/ml, respectively). The MIC90 of ciprofloxacin for M. fortuitum was 0.5 microgram/ml. Only 14 to 28% of isolates of M. chelonae were susceptible to various quinolones. Most isolates of all three species were susceptible to the new aminoglycosides SCH 21420 and SCH 22591. The MIC90s of trospectomycin were 8 micrograms/ml for M. chelonae, 32 micrograms/ml for Mycobacterium species, and > 64 micrograms/ml for M. fortuitum.

Full text

PDF
135

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Azadian B. S., Beck A., Curtis J. R., Cherrington L. E., Gower P. E., Phillips M., Eastwood J. B., Nicholls J. Disseminated infection with mycobacterium chelonei in a haemodialysis patient. Tubercle. 1981 Dec;62(4):281–284. doi: 10.1016/s0041-3879(81)80009-8. [DOI] [PubMed] [Google Scholar]
  2. Barnes A. C., Lewin C. S., Hastings T. S., Amyes S. G. In vitro activities of 4-quinolones against the fish pathogen Aeromonas salmonicida. Antimicrob Agents Chemother. 1990 Sep;34(9):1819–1820. doi: 10.1128/aac.34.9.1819. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Barry A. L., Jones R. N., Thornsberry C., Ayers L. W., Gavan T. L., Gerlach E. H. In vitro activity of the aryl-fluoroquinolones A-56619 and A-56620 and evaluation of disk susceptibility tests. Eur J Clin Microbiol. 1986 Feb;5(1):18–22. doi: 10.1007/BF02013455. [DOI] [PubMed] [Google Scholar]
  4. Barry A. L., Thornsberry C., Jones R. N. In vitro evaluation of A-56619 and A-56620, two new quinolones. Antimicrob Agents Chemother. 1986 Jan;29(1):40–43. doi: 10.1128/aac.29.1.40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Becker G. J., Walker R. G., Dziukas L. J., Harvey K. J., Valentine R., Kincaid-Smith P. Renal infection with Mycobacterium chelonei. Aust N Z J Med. 1980 Feb;10(1):44–47. doi: 10.1111/j.1445-5994.1980.tb03417.x. [DOI] [PubMed] [Google Scholar]
  6. Blaser J., Münch R., Lüthy R. Human pharmacology of 5-epi-sisomicin (Sch 22591) following intramuscular administration. J Antimicrob Chemother. 1987 Feb;19(2):233–238. doi: 10.1093/jac/19.2.233. [DOI] [PubMed] [Google Scholar]
  7. Dalovisio J. R., Pankey G. A. In vitro susceptiiblity of Mycobacterium fortuitum and Mycobacterium chelonei to amikacin. J Infect Dis. 1978 Mar;137(3):318–321. doi: 10.1093/infdis/137.3.318. [DOI] [PubMed] [Google Scholar]
  8. Dalovisio J. R., Pankey G. A., Wallace R. J., Jones D. B. Clinical usefulness of amikacin and doxycycline in the treatment of infection due to Mycobacterium fortuitum and Mycobacterium chelonei. Rev Infect Dis. 1981 Sep-Oct;3(5):1068–1074. doi: 10.1093/clinids/3.5.1068. [DOI] [PubMed] [Google Scholar]
  9. Forstall G. J., Knapp C. C., Washington J. A. Activity of new quinolones against ciprofloxacin-resistant staphylococci. Antimicrob Agents Chemother. 1991 Aug;35(8):1679–1681. doi: 10.1128/aac.35.8.1679. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Furet Y. X., Pechère J. C. Newly documented antimicrobial activity of quinolones. Eur J Clin Microbiol Infect Dis. 1991 Apr;10(4):249–254. doi: 10.1007/BF01966997. [DOI] [PubMed] [Google Scholar]
  11. Gerster J. F., Rohlfing S. R., Pecore S. E., Winandy R. M., Stern R. M., Landmesser J. E., Olsen R. A., Gleason W. B. Synthesis, absolute configuration, and antibacterial activity of 6,7-dihydro-5,8-dimethyl-9-fluoro-1-oxo-1H,5H- benzo[ij]quinolizine-2-carboxylic acid. J Med Chem. 1987 May;30(5):839–843. doi: 10.1021/jm00388a016. [DOI] [PubMed] [Google Scholar]
  12. Graybill J. R., Silva J., Jr, Fraser D. W., Lordon R., Rogers E. Disseminated mycobacteriosis due to Mycobacterium abcessus in two recipients of renal homografts. Am Rev Respir Dis. 1974 Jan;109(1):4–10. doi: 10.1164/arrd.1974.109.1.4. [DOI] [PubMed] [Google Scholar]
  13. Haemers A., Leysen D. C., Bollaert W., Zhang M. Q., Pattyn S. R. Influence of N substitution on antimycobacterial activity of ciprofloxacin. Antimicrob Agents Chemother. 1990 Mar;34(3):496–497. doi: 10.1128/aac.34.3.496. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Jones R. N., Johnson D. M., Barrett M. S., Erwin M. E. Antimicrobial activity of isepamicin (SCH21420, 1-N-HAPA gentamicin B) combinations with cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, imipenem, mezlocillin and piperacillin tested against gentamicin-resistant and susceptible gram-negative bacilli and enterococci. J Chemother. 1991 Oct;3(5):289–294. doi: 10.1080/1120009x.1991.11739108. [DOI] [PubMed] [Google Scholar]
  15. Khardori N., Reuben A., Rosenbaum B., Rolston K., Bodey G. P. In vitro susceptibility of Xanthomonas (Pseudomonas) maltophilia to newer antimicrobial agents. Antimicrob Agents Chemother. 1990 Aug;34(8):1609–1610. doi: 10.1128/aac.34.8.1609. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Neu H. C., Chin N. X. In-vitro activity of two new quinolone antimicrobial agents, S-25930 and S-25932 compared with that of other agents. J Antimicrob Chemother. 1987 Feb;19(2):175–185. doi: 10.1093/jac/19.2.175. [DOI] [PubMed] [Google Scholar]
  17. Neu H. C. Synergy and antagonism of combinations with quinolones. Eur J Clin Microbiol Infect Dis. 1991 Apr;10(4):255–261. doi: 10.1007/BF01966998. [DOI] [PubMed] [Google Scholar]
  18. Piddock L. J., Andrews J. M., Diver J. M., Wise R. In vitro studies of S-25930 and S-25932, two new 4-quinolones. Eur J Clin Microbiol. 1986 Jun;5(3):303–310. doi: 10.1007/BF02017786. [DOI] [PubMed] [Google Scholar]
  19. Pierce P. F., DeYoung D. R., Roberts G. D. Mycobacteremia and the new blood culture systems. Ann Intern Med. 1983 Dec;99(6):786–789. doi: 10.7326/0003-4819-99-6-786. [DOI] [PubMed] [Google Scholar]
  20. Pottage J. C., Jr, Harris A. A., Trenholme G. M., Levin S., Kaplan R. L., Feczko J. M. Disseminated Mycobacterium chelonei infection: a report of two cases. Am Rev Respir Dis. 1982 Oct;126(4):720–722. doi: 10.1164/arrd.1982.126.4.720. [DOI] [PubMed] [Google Scholar]
  21. Rolston K. V., Ho D. H., LeBlanc B., Bodey G. P. Comparative in vitro activity of the two new 4-quinolones S-25930 and S-25932 against gram-positive bacteria isolated from cancer patients. Eur J Clin Microbiol Infect Dis. 1988 Oct;7(5):681–683. doi: 10.1007/BF01964254. [DOI] [PubMed] [Google Scholar]
  22. Rolston K. V., Ho D. H., LeBlanc B., Bodey G. P. In vitro evaluation of S-25930 and S-25932, two new quinolones, against aerobic gram-negative isolates from cancer patients. Antimicrob Agents Chemother. 1987 Jan;31(1):102–103. doi: 10.1128/aac.31.1.102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Rolston K. V., Ho D. H., LeBlanc B., Bodey G. P. In vitro evaluation of S-25930 and S-25932, two new quinolones, against aerobic gram-negative isolates from cancer patients. Antimicrob Agents Chemother. 1987 Jan;31(1):102–103. doi: 10.1128/aac.31.1.102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Rolston K. V., Messer M., Ho D. H. Comparative in vitro activities of newer quinolones against Pseudomonas species and Xanthomonas maltophilia isolated from patients with cancer. Antimicrob Agents Chemother. 1990 Sep;34(9):1812–1813. doi: 10.1128/aac.34.9.1812. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Sanders W. E., Jr, Hartwig C., Schneider N., Cacciatore R., Valdez H. Activity of amikacin against Mycobacteria in vitro and in murine tuberculosis. Tubercle. 1982 Sep;63(3):201–208. doi: 10.1016/s0041-3879(82)80031-7. [DOI] [PubMed] [Google Scholar]
  26. Sanders W. E., Jr, Hartwig E. C., Schneider N. J., Cacciatore R., Valdez H. Susceptibility of organisms in the Mycobacterium fortuitum complex to antituberculous and other antimicrobial agents. Antimicrob Agents Chemother. 1977 Aug;12(2):295–297. doi: 10.1128/aac.12.2.295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Shiritani Y., Yamaji S., Aoki A., Saigusa M., Yokoiyama S., Gato S., Tsuji A. [Synergistic activity of isepamicin and beta-lactam antibiotics against Pseudomonas aeruginosa in vitro and in vivo]. Jpn J Antibiot. 1988 Nov;41(11):1591–1599. [PubMed] [Google Scholar]
  28. Shonekan D., Mildvan D., Handwerger S. Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci. Antimicrob Agents Chemother. 1992 Jul;36(7):1570–1572. doi: 10.1128/aac.36.7.1570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Smith S. M. In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1986 Feb;29(2):325–326. doi: 10.1128/aac.29.2.325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Speert D. P., Munson D., Mitchell C., Johnson D. E., Thompson T. R., Ferrieri P., Wannamaker L. W. Mycobacterium chelonei septicemia in a premature infant. J Pediatr. 1980 Apr;96(4):681–683. doi: 10.1016/s0022-3476(80)80739-6. [DOI] [PubMed] [Google Scholar]
  31. Swenson J. M., Thornsberry C., Silcox V. A. Rapidly growing mycobacteria: testing of susceptibility to 34 antimicrobial agents by broth microdilution. Antimicrob Agents Chemother. 1982 Aug;22(2):186–192. doi: 10.1128/aac.22.2.186. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Swenson J. M., Wallace R. J., Jr, Silcox V. A., Thornsberry C. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother. 1985 Dec;28(6):807–811. doi: 10.1128/aac.28.6.807. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Tice A. D., Solomon R. J. Disseminated Mycobacterium chelonei infection: response to sulfonamides. Am Rev Respir Dis. 1979 Jul;120(1):197–201. doi: 10.1164/arrd.1979.120.1.197. [DOI] [PubMed] [Google Scholar]
  34. Venezia R. A., Prymas L. A., Shayegani A., Yocum D. M. In vitro activities of amifloxacin and two of its metabolites. Antimicrob Agents Chemother. 1989 May;33(5):762–766. doi: 10.1128/aac.33.5.762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Wallace R. J., Jr, Bedsole G., Sumter G., Sanders C. V., Steele L. C., Brown B. A., Smith J., Graham D. R. Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy. Antimicrob Agents Chemother. 1990 Jan;34(1):65–70. doi: 10.1128/aac.34.1.65. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Wallace R. J., Jr, Swenson J. M., Silcox V. A., Bullen M. G. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities. J Infect Dis. 1985 Sep;152(3):500–514. doi: 10.1093/infdis/152.3.500. [DOI] [PubMed] [Google Scholar]
  37. Watanabe M., Inoue M., Mitsuhashi S. In vitro activity of amifloxacin against outer membrane mutants of the family Enterobacteriaceae and frequency of spontaneous resistance. Antimicrob Agents Chemother. 1989 Nov;33(11):1837–1840. doi: 10.1128/aac.33.11.1837. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES